| 2023年年报 | 2023年中报 | 2022年年报 | 2022年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 大容量注射液(元) | 10,109,201,289.00 | 5,026,896,181.00 | 9,451,538,327.00 | 4,398,962,997.00 |
| 非大容量注射液(元) | 9,056,854,750.00 | 4,296,867,540.00 | 8,273,962,490.00 | 4,140,018,814.00 |
| 研发项目(元) | 1,548,237,291.00 | 1,043,182,061.00 | 751,753,090.00 | 385,019,641.00 |
| 其他业务(元) | - | - | - | 200,620,307.00 |
| 其他(元) | - | 366,980,827.00 | 435,399,556.00 | - |
| 营业成本(元) | ||||
| 大容量注射液(元) | 3,640,646,003.00 | 1,799,083,378.00 | 3,424,774,456.00 | 1,535,145,103.00 |
| 非大容量注射液(元) | 5,280,811,074.00 | 2,585,874,661.00 | 4,979,787,833.00 | 2,392,165,148.00 |
| 研发项目(元) | 748,819,711.00 | 337,202,865.00 | 251,816,331.00 | 112,139,718.00 |
| 其他业务(元) | - | - | - | 142,262,726.00 |
| 其他(元) | - | 292,842,502.00 | 302,820,546.00 | - |
| 毛利(元) | ||||
| 大容量注射液(元) | 6,468,555,286.00 | 3,227,812,803.00 | 6,026,763,871.00 | 2,863,817,894.00 |
| 非大容量注射液(元) | 3,776,043,676.00 | 1,710,992,879.00 | 3,294,174,657.00 | 1,747,853,666.00 |
| 研发项目(元) | 799,417,580.00 | 705,979,196.00 | 499,936,759.00 | 272,879,923.00 |
| 其他业务(元) | - | - | - | 58,357,581.00 |
| 其他(元) | - | 74,138,325.00 | 132,579,010.00 | - |
| 毛利率(%) | ||||
| 大容量注射液(%) | 63.99 | 64.21 | 63.76 | 65.10 |
| 非大容量注射液(%) | 41.69 | 39.82 | 39.81 | 42.22 |
| 研发项目(%) | 51.63 | 67.68 | 66.50 | 70.87 |
| 其他业务(%) | - | - | - | 29.09 |
| 其他(%) | - | 20.20 | 30.45 | - |
| 收入构成(%) | ||||
| 大容量注射液(%) | 48.80 | 46.83 | 49.97 | 48.21 |
| 非大容量注射液(%) | 43.72 | 40.03 | 43.75 | 45.37 |
| 研发项目(%) | 7.47 | 9.72 | 3.97 | 4.22 |
| 其他业务(%) | - | - | - | 2.20 |
| 其他(%) | - | 3.42 | 2.30 | - |
| 毛利构成(%) | ||||
| 大容量注射液(%) | 58.57 | 56.44 | 60.55 | 57.94 |
| 非大容量注射液(%) | 34.19 | 29.92 | 33.10 | 35.36 |
| 研发项目(%) | 7.24 | 12.34 | 5.02 | 5.52 |
| 其他业务(%) | - | - | - | 1.18 |
| 其他(%) | - | 1.30 | 1.33 | - |